PharmAla Biotech Holdings Inc. announced that it had entered into a binding sales agreement with Numinus Wellness Inc. to provide its GMP LaNeo? MDMA for a prospective clinical trial.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.115 CAD | -8.00% | -8.00% | -17.86% |
05-03 | PharmAla Up Near 8% As Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy | MT |
04-23 | Red Light Holland Corp. Initiates Psilocybin Extraction Phase with PharmAla | CI |
1st Jan change | Capi. | |
---|---|---|
-17.86% | 7.3M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- MDMA Stock
- News Pharmala Biotech Holdings Inc.
- Pharmala Biotech Holdings Inc. Signs Sale Agreement with Numinus